1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Evotec Extends Anti-Infectives Footprint With Helmholtz Collaboration

 
• By John Davis

Building on a leading position in anti-infectives research, Evotec aims to develop a new class of antibacterials based on cystobactamids, which are found in slime bacteria and have potent activity against serious bacterial pathogens.  

OrangeBacteria
Slime bacteria are a relatively new resource for new antibiotics • Source: Shutterstock

Nature has long proven to be a great source of novel antibiotics, and the European drug discovery and development company, Evotec AG, is linking up with a leading research institute in Germany, the Helmholtz Center for Infection Research (HZI), to develop cystobactamids, potentially a new class of antibiotics which are found in myxobacteria, or slime bacteria.

This is the latest collaboration by Evotec to feature a major center of academic excellence in infection research: the Hamburg, Germany-based company is already working with Harvard University on discovering small-molecule inhibitors of bacterial cell wall synthesis, under a May 2013

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.